

# Brigitte Wildemann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4975931/publications.pdf>

Version: 2024-02-01

95  
papers

8,748  
citations

53794

45  
h-index

43889

91  
g-index

98  
all docs

98  
docs citations

98  
times ranked

7064  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19-related severe MS exacerbation with life-threatening Takotsubo cardiomyopathy in a previously stable patient and interference of MS therapy with long-term immunity against SARS-CoV-2. <i>Journal of Neurology</i> , 2022, 269, 1138-1141.	3.6	3
2	Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. <i>European Journal of Neurology</i> , 2022, 29, 555-563.	3.3	85
3	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17
4	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.1	14
5	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	7.2	82
6	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	64
7	Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis. <i>Journal of Neurology</i> , 2022, 269, 5420-5430.	3.6	2
8	MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. <i>Acta Neuropathologica</i> , 2021, 141, 127-131.	7.7	21
9	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	3.3	11
10	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1007-1013.	1.9	22
11	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , 2021, 158, 522-538.	3.9	18
12	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	41
13	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devices—A Critical Appraisal. <i>Cells</i> , 2021, 10, 1232.	4.1	8
14	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. <i>Brain</i> , 2021, 144, 3126-3141.	7.6	14
15	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38
16	Transient MOG antibody seroconversion associated with immunomodulating therapy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101420.	2.0	4
17	Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2020, 153, 650-661.	3.9	44
18	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	30.5	232

#	ARTICLE	IF	CITATIONS
19	Genetic determinants of the humoral immune response in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e827.	6.0	7
20	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	7.2	84
21	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	7.2	44
22	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	1.9	66
23	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
24	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
25	Is APOE $\epsilon$ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	6.0	11
26	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
27	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	4.2	29
28	Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment. <i>Frontiers in Immunology</i> , 2019, 10, 1204.	4.8	18
29	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	9.0	48
30	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019, 10, 5779.	12.8	87
31	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. <i>Journal of Neurology</i> , 2019, 266, 165-173.	3.6	20
32	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.6	24
33	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e446.	6.0	54
34	Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. <i>Journal of Neurology</i> , 2018, 265, 239-252.	3.6	20
35	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
36	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e480.	6.0	19

#	ARTICLE	IF	CITATIONS
37	Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 114-118.	3.0	20
38	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , 2017, 264, 341-349.	3.6	18
39	Failure of alemtuzumab therapy to control MOG encephalomyelitis. <i>Neurology</i> , 2017, 89, 207-209.	1.1	27
40	From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. <i>Journal of Neuroimmunology</i> , 2017, 309, 77-81.	2.3	27
41	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
42	Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography. <i>Annals of Neurology</i> , 2017, 82, 676-685.	5.3	54
43	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2017, 4, e363.	6.0	37
44	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. <i>Journal of the Neurological Sciences</i> , 2017, 381, 240-244.	0.6	29
45	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial study protocol. <i>BMJ Open</i> , 2016, 6, e010956.	1.9	46
46	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228
47	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	7.2	351
48	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.2	686
49	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.2	217
50	Sodium MRI in Multiple Sclerosis is Compatible with Intracellular Sodium Accumulation and Inflammation-Induced Hyper-Cellularity of Acute Brain Lesions. <i>Scientific Reports</i> , 2016, 6, 31269.	3.3	20
51	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	1.9	184
52	Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 301, 53-60.	2.3	11
53	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	10.3	133
54	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.2	202

#	ARTICLE	IF	CITATIONS
55	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	7.2	23
56	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
57	Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 294, 18-26.	2.3	24
58	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in "pattern II multiple sclerosis" and brain biopsy findings in a MOG-IgG-positive case. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1541-1549.	3.0	96
59	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	6.0	53
60	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0155322.	2.5	4
61	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	1.3	15
62	Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e86.	6.0	29
63	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1521-1532.	3.0	25
64	A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. <i>Immunology and Cell Biology</i> , 2015, 93, 396-405.	2.3	34
65	Neurology "the next 10 years. <i>Nature Reviews Neurology</i> , 2015, 11, 658-664.	10.1	7
66	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015, 85, 610-618.	1.1	50
67	Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg. <i>Journal of Neuroimmunology</i> , 2015, 278, 60-68.	2.3	8
68	Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. <i>Journal of Neuroinflammation</i> , 2014, 11, 206.	7.2	50
69	Immunopathogenesis of Neuromyelitis Optica. <i>Advances in Immunology</i> , 2014, 121, 213-242.	2.2	55
70	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1189-1197.	3.0	70
71	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
72	Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. <i>Journal of Neuroimmunology</i> , 2014, 267, 102-104.	2.3	37

#	ARTICLE	IF	CITATIONS
73	The history of neuromyelitis optica. <i>Journal of Neuroinflammation</i> , 2013, 10, 8.	7.2	188
74	Aquaporin-4 Antibodies (NMO) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature. <i>Brain Pathology</i> , 2013, 23, 661-683.	4.1	214
75	Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis. <i>Journal of Immunology</i> , 2013, 190, 4965-4970.	0.8	52
76	The expanding range of autoimmune disorders of the nervous system. <i>Lancet Neurology</i> , The, 2013, 12, 22-24.	10.2	14
77	GABAB receptor antibodies in paraneoplastic cerebellar ataxia. <i>Journal of Neuroimmunology</i> , 2013, 256, 94-96.	2.3	62
78	Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. <i>Journal of Neuroinflammation</i> , 2013, 10, 7.	7.2	42
79	T-cell homeostasis in pediatric multiple sclerosis. <i>Neurology</i> , 2013, 81, 784-792.	1.1	62
80	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.2	593
81	B cells undergo unique compartmentalized redistribution in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2011, 37, 289-299.	6.5	58
82	Intracerebral Human Regulatory T Cells: Analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e17988.	2.5	85
83	The interleukin-7 receptor $\alpha$ chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. <i>European Journal of Immunology</i> , 2011, 41, 845-853.	2.9	42
84	A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. <i>Journal of Neuroinflammation</i> , 2010, 7, 21.	7.2	60
85	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010, 298, 158-162.	0.6	169
86	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. <i>Nature Reviews Neurology</i> , 2010, 6, 383-392.	10.1	384
87	Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009, 216, 113-117.	2.3	105
88	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 202-214.	2.5	286
89	Interferon Beta-Induced Restoration of Regulatory T-Cell Function in Multiple Sclerosis Is Prompted by an Increase in Newly Generated Naive Regulatory T Cells. <i>Archives of Neurology</i> , 2008, 65, 1434.	4.5	86
90	Prevalence of Newly Generated Naive Regulatory T Cells (Treg) Is Critical for Treg Suppressive Function and Determines Treg Dysfunction in Multiple Sclerosis. <i>Journal of Immunology</i> , 2007, 179, 1322-1330.	0.8	219

#	ARTICLE	IF	CITATIONS
91	Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. <i>European Journal of Immunology</i> , 2005, 35, 3343-3352.	2.9	380
92	Thymic Export Function and T Cell Homeostasis in Patients with Relapsing Remitting Multiple Sclerosis. <i>Journal of Immunology</i> , 2003, 171, 432-437.	0.8	130
93	Rapid distinction of acute demyelinating disorders and central nervous system lymphoma by molecular analysis of cerebrospinal fluid cells. <i>Journal of Neurology</i> , 2001, 248, 127-130.	3.6	15
94	Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. <i>Annals of Neurology</i> , 2000, 47, 211-217.	5.3	21
95	Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study. <i>European Journal of Neurology</i> , 1999, 6, 531-538.	3.3	33